These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Flowcytometric analysis of bronchoalveolar lavage fluid cells in polymyositis/dermatomyositis with interstitial pneumonia. Kourakata H, Takada T, Suzuki E, Enomoto K, Saito I, Taguchi Y, Tsukada H, Nakano M, Arakawa M. Respirology; 1999 Sep; 4(3):223-8. PubMed ID: 10489663 [Abstract] [Full Text] [Related]
24. Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. Matsushita T, Hasegawa M, Fujimoto M, Hamaguchi Y, Komura K, Hirano T, Horikawa M, Kondo M, Orito H, Kaji K, Saito Y, Matsushita Y, Kawara S, Yasui M, Seishima M, Ozaki S, Kuwana M, Ogawa F, Sato S, Takehara K. J Rheumatol; 2007 May; 34(5):1012-8. PubMed ID: 17309126 [Abstract] [Full Text] [Related]
27. Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52. Yamasaki Y, Satoh M, Mizushima M, Okazaki T, Nagafuchi H, Ooka S, Shibata T, Nakano H, Ogawa H, Azuma K, Maeda A, Tonooka K, Ito H, Takakuwa Y, Inoue M, Mitomi H, Kiyokawa T, Tsuchida K, Matsushita H, Mikage H, Murakami Y, Chan JY, Ozaki S, Yamada H. Mod Rheumatol; 2016 May; 26(3):403-9. PubMed ID: 26344678 [Abstract] [Full Text] [Related]
35. Predictive Factors for the Long-Term Deterioration of Pulmonary Function in Interstitial Lung Disease Associated with Anti-Aminoacyl-tRNA Synthetase Antibodies. Yamakawa H, Hagiwara E, Kitamura H, Iwasawa T, Otoshi R, Aiko N, Katano T, Shintani R, Ikeda S, Okuda R, Sekine A, Baba T, Iso S, Kuwano K, Sato S, Ogura T. Respiration; 2018 Sep 24; 96(3):210-221. PubMed ID: 29768275 [Abstract] [Full Text] [Related]
36. [Clinical and pathological findings of patients with interstitial lung disease associated with antisynthetase]. Hara H, Inoue Y, Sato T. Nihon Kokyuki Gakkai Zasshi; 2005 Nov 24; 43(11):652-63. PubMed ID: 16366363 [Abstract] [Full Text] [Related]
37. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies. Chen F, Li S, Wang T, Shi J, Wang G. Am J Med Sci; 2018 Jan 24; 355(1):48-53. PubMed ID: 29289262 [Abstract] [Full Text] [Related]
38. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Arthritis Rheum; 2011 Nov 24; 63(11):3439-47. PubMed ID: 21702020 [Abstract] [Full Text] [Related]
39. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases]. Xie MM, Zou RY, Li Y, Liu Y, Chen LL, Liu XQ, Zhao Q, Ding JJ, Chen ZY, Cai HR. Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct 12; 42(10):765-770. PubMed ID: 31594111 [Abstract] [Full Text] [Related]
40. Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody. Isoda K, Kotani T, Takeuchi T, Kiboshi T, Hata K, Ishida T, Otani K, Kamimori T, Fujiwara H, Shoda T, Makino S. Rheumatol Int; 2017 Aug 12; 37(8):1335-1340. PubMed ID: 28451794 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]